CapsoVision (CV) Corporate Presentation summary

Vision and innovation

• Aims to transform GI detection and screening with ingestible capsules for noninvasive, multi-cancer screening using AI image analysis.

• Focuses on empowering clinical practice through innovation and advanced technology.

Product portfolio and technology

• CapsoCam Plus offers 360° panoramic imaging for small bowel, FDA cleared, with over 143,000 uses as of June 2025.

• Wire-free, cloud-based workflow enables tele-supervised ingestion and at-home retrieval, improving convenience.

• Proprietary AI technology assists physicians, with FDA clearance for AI module expected by Q1 2026.

• CapsoCam Colon targets non-invasive colon visualization, with FDA submission in June 2025 and Gen 2 in Q1 2026.

Market opportunity and financials

• Small bowel capsule endoscopy market forecasted to reach $335M by 2030, with 2024 revenue at $11.8M and 20% CAGR.

• Colon capsule endoscopy initial U.S. target market estimated at $1B, driven by Medicare reimbursement and high-risk patient needs.

• Q2 2025 revenue reached $3.3M, 17% year-over-year growth, 55% gross margin, and 75% growth in new accounts.